Company intelligence / Profile preview

Red Arrow Therapeutics

Cambridge, Massachusetts, USAredarrowtx.com ↗

Ownership: Private
Employees: ~20
Development stage: Preclinical

Overview

Red Arrow Therapeutics is developing a nanopolymer-based drug delivery platform to safely and effectively deliver biologic drugs, with its lead program focused on an IL‑12 prodrug for cancer immunotherapy. Preclinical data show strong anti-tumor efficacy and reduced toxicity compared to native IL‑12. IND filing is planned for 2027[1][3].

Therapeutic areas: OncologyWomen's Health
Modalities: Nanopolymer drug delivery systemsPolymer-protein conjugatesProdrug-like proteinsImmunotherapy (notably Interleukin-based therapeutics)
Industry: Biotech

Drug pipeline

6 assets

RA-004

Preclinical

5 more assets in the full pipeline.

Request access →

Partnerships

ASKA Pharmaceutical Co., Ltd. – joint research for novel preeclampsia treatment[1]

Beyond the preview

Go deeper on Red Arrow Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Red Arrow Therapeutics.

Explore the full profile